Cochrane Abstracts
Tamoxifen for relapse of ovarian cancer
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Tamoxifen for Relapse of Ovarian Cancer." Cochrane Abstracts, John Wiley & Sons, Inc, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/434175/2/Tamoxifen_for_relapse_of_ovarian_cancer.
Tamoxifen for relapse of ovarian cancer. Cochrane Abstracts. John Wiley & Sons, Inc; 2025. https://evidence.unboundmedicine.com/evidence/view/Cochrane/434175/2/Tamoxifen_for_relapse_of_ovarian_cancer. Accessed November 3, 2025.
Tamoxifen for relapse of ovarian cancer. (2025). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/434175/2/Tamoxifen_for_relapse_of_ovarian_cancer
Tamoxifen for Relapse of Ovarian Cancer [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2025. [cited 2025 November 03]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/434175/2/Tamoxifen_for_relapse_of_ovarian_cancer.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Tamoxifen for relapse of ovarian cancer
ID - 434175
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/434175/2/Tamoxifen_for_relapse_of_ovarian_cancer
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
